CHIEF SCIENTIFIC OFFICER · Enliven Therapeutics, Inc. · Common Stock
Side
SELL
Value
$268K
Shares
12.0K
Price
$22.3
Executed
Nov 19, 2025
Disclosed
Nov 21, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 19 executedNov 21, 2025 disclosed
ELVN · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering+10 / 15
2 other actors traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Lyssikatos Joseph P filed this Form 4 reporting a open-market sale of ELVN on Nov 19, 2025. It became public on Nov 21, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
CHIEF SCIENTIFIC OFFICER
Lyssikatos Joseph Pcik:0001967150
Issuer
Enliven Therapeutics, Inc.cik:0001672619
Revision history · 0
No field has changed since this record was first ingested.
